124 related articles for article (PubMed ID: 11436202)
21. Plasma chromogranin A in pheochromocytoma, primary hyperparathyroidism and pituitary adenoma in comparison with catecholamine, parathyroid hormone and pituitary hormones.
Kimura N; Miura W; Noshiro T; Mizunashi K; Hanew K; Shimizu K; Watanabe T; Shibukawa S; Sohn HE; Abe K; Miura Y; Nagura H
Endocr J; 1997 Apr; 44(2):319-27. PubMed ID: 9228469
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of chromogranin A expression in serum and tissues of breast cancer patients.
Giovanella L; Marelli M; Ceriani L; Giardina G; Garancini S; Colombo L
Int J Biol Markers; 2001; 16(4):268-72. PubMed ID: 11820723
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic specificity of serum chromogranin-A for pheochromocytoma in patients with renal dysfunction.
Canale MP; Bravo EL
J Clin Endocrinol Metab; 1994 May; 78(5):1139-44. PubMed ID: 8175970
[TBL] [Abstract][Full Text] [Related]
24. Characterisation of N-terminal chromogranin A and chromogranin B in mammals by region-specific radioimmunoassays and chromatographic separation methods.
Stridsberg M; Angeletti RH; Helle KB
J Endocrinol; 2000 Jun; 165(3):703-14. PubMed ID: 10828855
[TBL] [Abstract][Full Text] [Related]
25. Serum chromogranin-A assay in differential diagnosis of incidentally discovered adrenal masses.
Giovanella L
Anticancer Res; 2005; 25(3A):1547-50. PubMed ID: 16033058
[TBL] [Abstract][Full Text] [Related]
26. Immunoassays for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans: correspondence in patients with neuroendocrine neoplasia.
Syversen U; Jacobsen MB; O'Connor DT; Rønning K; Waldum HL
Neuropeptides; 1994 Mar; 26(3):201-6. PubMed ID: 8208366
[TBL] [Abstract][Full Text] [Related]
27. Circulating chromogranin a and hormone refractory prostate cancer chemotherapy.
Cabrespine A; Guy L; Gachon F; Curé H; Chollet P; Bay JO
J Urol; 2006 Apr; 175(4):1347-52. PubMed ID: 16515996
[TBL] [Abstract][Full Text] [Related]
28. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy.
Sanduleanu S; De Bruïne A; Stridsberg M; Jonkers D; Biemond I; Hameeteman W; Lundqvist G; Stockbrügger RW
Eur J Clin Invest; 2001 Sep; 31(9):802-11. PubMed ID: 11589723
[TBL] [Abstract][Full Text] [Related]
29. Serum chromogranin A in the diagnosis and follow-up of neuroendocrine tumors of the gastroenteropancreatic tract.
Schürmann G; Raeth U; Wiedenmann B; Buhr H; Herfarth C
World J Surg; 1992; 16(4):697-701; discussion 701-2. PubMed ID: 1413839
[TBL] [Abstract][Full Text] [Related]
30. A comparison between the diagnostic value of gonadotropins, alpha-subunit, and chromogranin-A and their response to thyrotropin-releasing hormone in clinically nonfunctioning, alpha-subunit-secreting, and gonadotroph pituitary adenomas.
Nobels FR; Kwekkeboom DJ; Coopmans W; Hoekstra R; De Herder WW; Bouillon R; Lamberts SW
J Clin Endocrinol Metab; 1993 Sep; 77(3):784-9. PubMed ID: 7690365
[TBL] [Abstract][Full Text] [Related]
31. An Italian program of external quality control for chromogranin A (CgA) assay: state of the art of CgA measurement.
Italian Network for Quality Assessment of Tumor Biomarkers Group
Int J Biol Markers; 2005; 20(4):264-8. PubMed ID: 16398409
[TBL] [Abstract][Full Text] [Related]
32. Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas.
Abou-Saif A; Gibril F; Ojeaburu JV; Bashir S; Entsuah LK; Asgharian B; Jensen RT
Cancer; 2003 Jul; 98(2):249-61. PubMed ID: 12872342
[TBL] [Abstract][Full Text] [Related]
33. Chromogranin A and chromogranin B are sensitive circulating markers for phaeochromocytoma.
Stridsberg M; Husebye ES
Eur J Endocrinol; 1997 Jan; 136(1):67-73. PubMed ID: 9037129
[TBL] [Abstract][Full Text] [Related]
34. A comparison between three commercial kits for chromogranin A measurements.
Stridsberg M; Eriksson B; Oberg K; Janson ET
J Endocrinol; 2003 May; 177(2):337-41. PubMed ID: 12740022
[TBL] [Abstract][Full Text] [Related]
35. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
[TBL] [Abstract][Full Text] [Related]
36. A panel of 11 region-specific radioimmunoassays for measurements of human chromogranin A.
Stridsberg M; Eriksson B; Oberg K; Janson ET
Regul Pept; 2004 Mar; 117(3):219-27. PubMed ID: 14749043
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of elevated serum chromogranin A levels.
Syversen U; Ramstad H; Gamme K; Qvigstad G; Falkmer S; Waldum HL
Scand J Gastroenterol; 2004 Oct; 39(10):969-73. PubMed ID: 15513336
[TBL] [Abstract][Full Text] [Related]
38. Chromogranin A peptide-specific antisera and high-performance size exclusion chromatography demonstrate amino-terminal and carboxy-terminal fragments of the native molecule in human cell lines.
Brandt DW; Burton DW; Hogue-Angeletti R; Deftos LJ
Proc Soc Exp Biol Med; 1994 Apr; 205(4):316-20. PubMed ID: 8171054
[TBL] [Abstract][Full Text] [Related]
39. Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate.
Deftos LJ; Nakada S; Burton DW; di Sant'Agnese PA; Cockett AT; Abrahamsson PA
Urology; 1996 Jul; 48(1):58-62. PubMed ID: 8693652
[TBL] [Abstract][Full Text] [Related]
40. Chromogranin A assay and (131)I-MIBG scintigraphy for diagnosis and follow-up of pheochromocytoma.
d'Herbomez M; Gouze V; Huglo D; Nocaudie M; Pattou F; Proye C; Wémeau JL; Marchandise X
J Nucl Med; 2001 Jul; 42(7):993-7. PubMed ID: 11438617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
